Skip to content
Peptide Atlas
All peptides

GHK-Cu

Tier 3 · Reported use
Also known as GHK copper · Copper tripeptide-1

The strongest evidence present is Tier 1: topical human randomized controlled trials are described by several sources (e.g., a 1994 vehicle-controlled wound-healing RCT, a diabetic ulcer RCT of N=40, and a post-CO2 laser RCT of N=13 per Apotheon; four topical RCTs per Peptide Garden). However, sources disagree on whether any human RCTs exist, and the evidence base is heavily weighted toward tier-3 vendor/educational pages plus tier-2 animal and in-vitro work. Critically, no human data exist for injectable/systemic GHK-Cu — all injectable claims are animal-model, in-vitro, or extrapolation. One review (PMID 41966639) flags GHK-Cu as an unapproved gray-market peptide with scarce rigorous human safety data.

Half-life
~0.75 h
Routes
Topical · Subcutaneous (no human data; vendor protocols only) · Intra-articular (animal studies) · Intranasal (animal studies) · Intramuscular (listed)
Goals
healing · longevity · cognitive
Cost / mg
Not recorded

How it works

Multiple sources describe GHK-Cu as the copper complex of a naturally occurring three-amino-acid peptide (glycine-histidine-lysine) bound to a copper(II) ion. Several sources report it was first isolated from human plasma in 1973 by Loren Pickart, who described it as a serum factor that made old cultured liver cells behave like younger ones. Sources note it occurs naturally in human plasma, saliva, and urine and is released when tissue is injured, and that endogenous levels are reported to decline with age (a 2022 review and other sources cite roughly 200 ng/mL at age 20 falling to about 80 ng/mL by age 60). The overall picture drawn by sources is that GHK-Cu delivers copper to cells, boosts collagen and other skin-matrix components, dampens inflammation, and switches many genes involved in repair, antioxidant defense, and tissue remodeling on or off — though one source cautions the headline '4,000+ genes' figure rests on a single unreplicated reanalysis.

Overview

Overview

GHK-Cu (also called GHK copper or copper tripeptide-1) is described by multiple sources as the copper complex of a naturally occurring three-amino-acid peptide, glycyl-L-histidyl-L-lysine (glycine, histidine, lysine), bound to a copper(II) ion14,15. Peptide Garden lists its CAS number as 49557-75-7(vendor claim). Reported molecular weights differ between sources: Peerless Peptides gives the free peptide as 340.4 and the 1:1 GHK-Cu complex as ~402.9, while other profiles cite ~403, 403.9, ~401.9, or 467 Da for the complex(vendor claim).

History and endogenous role

Several sources report that GHK-Cu was first isolated from human plasma in 1973 by Loren Pickart, who originally described it as a serum factor that prolonged the survival of cultured liver cells and made old liver cells behave like younger ones15. Several sources note GHK-Cu is a naturally occurring tripeptide found in human plasma, saliva, and urine, released during tissue injury from breakdown of extracellular matrix proteins10,14, and Peerless Peptides notes the Gly-His-Lys sequence occurs as an internal motif within human proteins including albumin, the alpha-2 chain of type I collagen, SPARC, and thrombospondin-1.

A 2022 review (PMID 35083444) and other sources report that endogenous GHK plasma levels average about 200 ng/mL at age 20, declining to about 80 ng/mL by age 60 — a roughly 60% decline said to track with slower wound healing, thinner skin, and reduced tissue repair12,14,15. A COPD study (PMID 36905132) reported plasma GHK levels of 70.27 ± 38.87 ng/mL in COPD patients versus 133.0 ± 54.54 ng/mL in healthy controls (P = 0.009), with GHK level correlating with pectoralis muscle area and inversely with TNF-α10.

Mechanistic claims

Gethealthspan describes GHK-Cu as forming a stable 1:1 complex with copper(II) and acting as a local tissue copper chaperone that neutralizes free copper toxicity via the Fenton reaction; HealthRx states it binds Cu2+ with a dissociation constant of ~10^-16 M. Sources describe copper as a required cofactor for lysyl oxidase, superoxide dismutase, tyrosinase, and cytochrome c oxidase, with GHK-Cu delivering copper to these cuproenzymes(vendor claim).

A widely repeated claim is that GHK/GHK-Cu modulates the expression of over 4,000 human genes — roughly 6% of the human genome — upregulating DNA repair, antioxidant, and collagen-synthesis genes while downregulating inflammation, fibrosis, and senescence genes (14, one source, one source, one source, one source, variously attributed to the Broad Institute Connectivity Map, a 2012 Pickart analysis, or Campbell and colleagues citing 4,048 genes at 1 µM). Peerless Peptides cautions that this figure derives from a single 2014 reanalysis of three cancer-cell-line microarray profiles and has not been independently replicated(vendor claim). MDPI reviews cite that ~31.2% (and elsewhere ~31%/~32%) of genes change by at least 50%1.

MDPI reviews and PMID 29986520 report GHK stimulates blood vessel and nerve outgrowth; increases collagen, elastin, and glycosaminoglycan synthesis; supports dermal fibroblast function; suppresses NFκB; supports DNA repair; and activates cell cleansing via the proteasome1. Peptide Breakdown states GHK-Cu promotes synthesis of collagen types I, III, and V, elastin, decorin, and proteoglycans, and both activates and inhibits matrix metalloproteinases as needed for remodeling(vendor claim). AMD Alliance states it reduces IL-6, promotes angiogenesis, and helps maintain stem-cell proliferative potential15; PeptideWiki adds proposed increases in VEGF, FGF, and NGF and modulation of iron release from ferritin. A review (PMID 41490200) reports GHK-Cu among peptides modulating PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK networks4. Target-level studies report GHK-Cu directly binds and activates SIRT1 (PMID 36905132) and binds PRDX6 (PMID 38879894), and in a colitis model upregulated SIRT1 while suppressing phosphorylated STAT3, RORγt, and Th17 cells (PMID 40672369). Peptide Guides adds that copper-free or dephosphorylated analogs show substantially reduced activity(vendor claim).

Evidence base and use cases

Several sources describe GHK-Cu's primary studied use cases as wound healing, skin repair and regeneration, collagen synthesis, tightening loose/aged skin, reducing fine lines and wrinkles, improving elasticity and clarity, UV protection, and (proposed) hair growth/thickness1,6,8. Peerless Peptides notes a thirty-year life as a registered cosmetic ingredient(vendor claim).

Human topical evidence is the strongest tier present but is contested. Peerless Peptides describes a 1994 randomized, vehicle-controlled wound-healing human trial while noting a 2006 controlled trial found no objective benefit(vendor claim). Apotheon reports a positive diabetic ulcer RCT (N=40) showing a 77% versus 45% healing rate — and notes this remains unreplicated after 30 years — plus a post-CO2 laser RCT (N=13) that showed no objective benefit but higher patient satisfaction; Apotheon characterizes topical skin/wrinkle evidence overall as moderate, with no placebo-controlled wrinkle RCTs despite decades of cosmetic use14. AMD Alliance reports a 12-week study of 71 women with photoaging in which a GHK-Cu cream significantly improved skin laxity, clarity, and firmness and was described as more effective than vitamin C and retinoic acid15. Peptidings, Peptide Garden, Peptide Guides, and Gethealthspan variously cite four or several small topical RCTs (typically 20–60 participants, 8–12 weeks) generally favoring GHK-Cu over vehicle at 0.1–1% concentrations(vendor claim). Peptidings lists registered trials including NCT05239615 (topical photoaging, Phase II completed 2024), NCT04892136 (hair growth, Phase I/II terminated 2023), and NCT02898454 (androgenetic alopecia, completed 2019)(vendor claim). Reviews note a surprising absence of clinical studies given widespread cosmetic use (PMID 399635748) and no clinical data for musculoskeletal conditions (PMID 414764243).

Animal and in-vitro work is more extensive. An MDPI review reports tissue-repair benefits demonstrated in animal models for skin, lung connective tissue, bony tissue, liver, and stomach lining1. Apotheon reports spinal cord injury repair with motor recovery in rats, GI healing via SIRT1/STAT3 in mouse colitis, lung fibrosis protection via PRDX6, and hair growth via Wnt/β-catenin in mice14. An ACL reconstruction rat study (PMID 25731775, 72 rats) found smaller knee laxity difference and higher graft stiffness at 6 weeks but no significant differences at 12 weeks13. A cigarette-smoking study (PMID 36905132) reported reduced muscle mass loss and improved grip strength in mice10; a DSS colitis study (PMID 40672369) reported reduced inflammation and mucosal repair7; a silicosis study (PMID 38879894) reported attenuated lung fibrosis without significant systemic toxicity9; and DrOracle reports intranasal GHK-Cu improved cognition in aged mice. PeptideWiki cites 64 PubMed-verified studies and Peptide Garden cites 60+ animal/in-vitro studies(vendor claim). A biomanufacturing review describes GHK-Cu evolving from a dermatological ingredient into a model system for coordination chemistry and biomanufacturing2. Peptidings notes GHK-Cu differs mechanistically from tissue-repair peptides like BPC-157 and TB-500, with more human data for topical cosmetic use but essentially no human data for systemic therapeutic use(vendor claim). DrOracle states GHK-Cu exists only in research contexts with no FDA-approved indications and no established human dosing regimens(vendor claim).

What the research shows

151 findings extracted from the 18 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 2 human trial findings, 10 human study findings, 17 animal findings, 5 in vitro findings and 6 expert opinion findings.

  • human trialDiabetic ulcers: positive RCT with 77% vs 45% healing rate, N=4014

  • human trialPost-CO2 laser RCT, N=13, showed no objective benefit but higher patient satisfaction14

  • human studyGHK improves tissue repair in skin, lung connective tissue, boney tissue, liver, and stomach lining1

  • human studyGHK possesses multiple anti-cancer activities1

  • human studyGHK possesses anti-inflammatory actions1

  • human studyGHK provides lung protection and restoration of chronic obstructive pulmonary disease (COPD) fibroblasts1

  • human studyGHK has anti-anxiety activities1

  • human studyGHK has anti-pain activities1

Show 32 more findings

  • human studyGHK has anti-aggression activities1

  • human studyPlasma GHK levels were decreased in COPD patients compared to healthy controls10

  • human studyPlasma GHK levels in COPD patients were associated with pectoralis muscle area10

  • human studyIn a 12-week study involving 71 women with mild to advanced signs of photoaging, a facial cream containing GHK-Cu showed significant improvements in skin laxity, clarity, and firmness, and a reduction in the appearance of fine lines and wrinkles15

  • animalGHK's ability to improve tissue repair has been demonstrated for skin, lung connective tissue, boney tissue, liver, and stomach lining1

  • animalGHK provides lung protection and restoration of chronic obstructive pulmonary disease (COPD) fibroblasts1

  • animalGHK has anti-anxiety, anti-pain and anti-aggression activities1

  • animalIn LPS-induced inflammation model in vivo and in vitro, GHK-Cu@CMHA gel reduced levels of inflammatory factors5

  • animalGHK-Cu alleviated weight loss in DSS-induced UC mice7

  • animalGHK-Cu improved the disease activity index (DAI) in DSS-induced UC model7

  • animalGHK-Cu reduced colonic edema and shortening in UC mice7

  • animalGHK-Cu attenuated inflammatory damage in DSS-induced UC7

  • animalGHK-Cu increased goblet cell numbers in UC model7

  • animalGHK-Cu promoted mucosal repair in UC mice7

  • animalGHK-Cu attenuates lung inflammation and fibrosis in silicosis mice9

  • animalGHK-Cu has been shown to promote skin remodeling, wound healing and regeneration12

  • animalAt 6 weeks post-ACLR, GHK-Cu groups resulted in a smaller side-to-side difference in knee laxity compared to saline group (p = 0.009)13

  • animalNo significant difference in knee laxity at 12 weeks post-operation between GHK-Cu and saline groups13

  • animalThe graft complex in the 0.3 mg/ml GHK-Cu group had higher stiffness than saline group at 6 weeks post-operation (p = 0.026)13

  • animalNo significant difference in ultimate load, gait parameters, and histological scores among treatment groups13

  • animalSpinal cord injury repair in rat studies showing motor function recovery14

  • in vitroGHK possesses multiple anti-cancer activities1

  • in vitroGHK-Cu showed promise in wound healing and anti-inflammatory effects3

  • in vitroBased on cellular studies, GHK can be considered as an anti-wrinkle ingredient8

  • in vitroGHK-Cu did not significantly affect tyrosinase activity11

  • in vitroGHK-Cu led to elastase inhibition, reducing the rate of elastin degeneration and supporting the structural integrity of the skin11

  • expert opinionGHK-Cu has no clinical data supporting its use for musculoskeletal conditions3

  • expert opinionPreclinical studies on wound-healing peptides like GHK-Cu are promising, but there is a current lack of clinical trials4

  • expert opinionThere is a surprising absence of clinical studies using GHK-Cu and Pal-GHK despite their widespread use in cosmetic products8

  • expert opinionTopical use for skin and wrinkles: moderate evidence — one positive RCT, one negative RCT, several open-label trials14

  • expert opinionThe positive diabetic ulcer RCT is unreplicated after 30 years14

  • expert opinionNo placebo-controlled wrinkle RCTs exist despite decades of cosmetic use14

How it works

Based on 7 human study findings, 15 animal findings, 23 in vitro findings, 10 expert opinion findings and 18 theoretical findings.

  • human studyGHK stimulates blood vessel and nerve outgrowth1

  • human studyGHK increases collagen, elastin, and glycosaminoglycan synthesis1

  • human studyGHK supports the function of dermal fibroblasts1

  • human studyGHK suppresses NFκB1

  • human studyGHK supports DNA repair1

  • human studyGHK activates cell cleansing via the proteasome system1

  • human studyPlasma levels decline ~60% with aging (200 ng/mL age 20 → 80 ng/mL age 60), which correlates with reduced tissue repair capacity14

  • animalROS levels decreased in response to GHK-Cu@CMHA gel treatment5

Show 65 more findings

  • animalSuperoxide dismutase (SOD) activity was enhanced by GHK-Cu@CMHA gel5

  • animalH&E staining and Masson staining revealed significant collagen deposition with GHK-Cu@CMHA treatment5

  • animalGHK-Cu suppressed inflammatory cytokines TNF-α, IL-6, and IL-1β7

  • animalGHK-Cu upregulated SIRT1 protein expression in colon tissue and MCECs7

  • animalGHK-Cu suppressed phosphorylated p-STAT3 expression in colon tissue and MCECs7

  • animalGHK-Cu could inhibit RORγt expression in colon tissue of UC mice7

  • animalGHK-Cu may promote mucosal healing and enhance tight junction protein expression by regulating the SIRT1/STAT3 pathway7

  • animalGHK-Cu may reduce the number of Th17 cells7

  • animalGHK-Cu acts as a potential drug by attenuating alveolar macrophage oxidative stress, thereby attenuating the progression of pulmonary inflammation and fibrosis9

  • animalGHK-Cu protects against cigarette smoking-induced skeletal muscle dysfunction via SIRT1 pathway10

  • animalGI healing via SIRT1/STAT3 pathway in mouse colitis model14

  • animalLung fibrosis protection via PRDX6 targeting14

  • animalHair growth via Wnt/β-catenin pathway in mouse model14

  • animalMany unapproved peptides including GHK-Cu demonstrate favorable tissue repair and metabolic outcomes in animal models16

  • in vitroGHK (glycyl-l-histidyl-l-lysine) stimulates blood vessel and nerve outgrowth1

  • in vitroGHK increases collagen, elastin, and glycosaminoglycan synthesis1

  • in vitroGHK supports the function of dermal fibroblasts1

  • in vitroGHK has anti-inflammatory actions1

  • in vitroGHK suppresses NFκB, a molecule thought to accelerate diseases of aging1

  • in vitroGHK supports DNA repair1

  • in vitroGHK activates cell cleansing via the proteasome system1

  • in vitroThe number of human genes stimulated or suppressed by GHK with a change greater than or equal to 50% is 31.2%1

  • in vitroGHK-Cu was successfully loaded onto HAPs by electrostatic adsorption5

  • in vitroGHK-Cu exhibits known anti-inflammatory properties7

  • in vitroGHK-Cu facilitated MCECs healing by upregulating ZO-1 and Occludin expression in co-culture model7

  • in vitroGHK-Cu stimulant effect on MCECs healing is canceled after STAT3 silencing by siRNA7

  • in vitroMetal complexation and chemical modification with a hydrophobic moiety increase permeability of GHK peptide8

  • in vitroGHK-Cu can bind to peroxiredoxin 6 (PRDX6)9

  • in vitroGHK-Cu inhibits crystalline silica-induced oxidative stress in alveolar macrophages9

  • in vitroGHK-Cu rescued CSE-induced skeletal muscle dysfunction in C2C12 myotubes with increased myosin heavy chain expression and reduced MuRF1 and atrogin-1 expression10

  • in vitroGHK-Cu directly binds and activates SIRT1 with binding energy of -6.1 kcal/mol10

  • in vitroAnionic and cationic hydrogenated lecithin-based liposomes can be used as GHK-Cu skin delivery systems11

  • in vitroCationic liposomes showed higher bilayer fluidity than anionic liposomes11

  • in vitroGHK-Cu has anti-inflammatory and tissue remodeling properties12

  • in vitroGHK-Cu has prominent antioxidant and anti-inflammatory effects in in vitro and in vivo studies12

  • in vitroGHK affects expression of >4,000 human genes per Broad Institute Connectivity Map analysis — upregulating DNA repair, antioxidant systems, and collagen synthesis while downregulating inflammation, fibrosis, and cellular senescence14

  • in vitroGHK-Cu complexes can be formed when Cu ions pass through nanochannels modified with GHK peptide18

  • expert opinionGHK-Cu (glycyl-L-histidyl-L-lysine-Cu(II)) is a well-known activator of tissue remodeling13

  • expert opinionGHK-Cu is a naturally occurring copper-binding tripeptide (Gly-His-Lys + Cu²⁺) found in human plasma, released during tissue injury from extracellular matrix protein degradation14

  • expert opinionGHK-Cu is a tripeptide consisting of three amino acids—glycyl-L-histidyl-L-lysine—with a strong affinity for binding to copper ions (Cu2+)15

  • expert opinionGHK-Cu has the ability to make old liver cells behave like younger ones15

  • expert opinionGHK-Cu can modulate the activity of thousands of human genes, essentially resetting them to a younger, healthier state15

  • expert opinionGHK-Cu upregulates genes involved in antioxidant defense, tissue repair, and anti-inflammatory pathways while downregulating genes associated with inflammation and tissue destruction15

  • expert opinionGHK-Cu is a potent stimulator of collagen, elastin, glycosaminoglycans, and proteoglycans15

  • expert opinionGHK-Cu reduces the levels of key inflammatory cytokines like IL-615

  • expert opinionGHK-Cu promotes the formation of new blood vessels (angiogenesis)15

  • expert opinionGHK-Cu helps maintain the health and proliferative potential of stem cells15

  • theoreticalGHK-Cu can bind copper(II) ions1

  • theoreticalGHK-Cu is an endogenous tripeptide–metal complex2

  • theoreticalGHK-Cu has multifaceted biological roles in tissue repair, anti-inflammatory regulation, extracellular matrix remodeling, and redox homeostasis2

  • theoreticalKey production technologies include tandem-repeat expression, high-cell-density fermentation, inclusion-body-assisted purification, and Cu(II) complex stabilization2

  • theoreticalTherapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes3

  • theoreticalGHK-Cu is a wound-healing peptide that promotes angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation4

  • theoreticalTherapeutic peptides including GHK-Cu modulate molecular signaling networks such as PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK central to tissue regeneration, inflammation resolution, and neuromuscular recovery4

  • theoreticalGHK-Cu occurs naturally in the human body6

  • theoreticalGHK has capability of tissue regeneration and enhancement of collagen and glycosaminoglycans synthesis8

  • theoreticalGHK is able to increase nerve outgrowth and angiogenesis8

  • theoreticalCell penetrating peptides seem promising to increase skin permeation of GHK and its derivatives8

  • theoreticalSkin pretreatment with microneedles has potential to enhance permeation of GHK peptides8

  • theoreticalGHK, a tripeptide naturally occurring in human blood and urine, has antioxidant effects9

  • theoreticalGHK is a normal component of human plasma, saliva, and urine10

  • theoreticalGHK promotes tissue regeneration and acts as anti-inflammatory and antioxidant10

  • theoreticalGHK has a very high affinity for copper and forms the chelate GHK-Cu12

  • theoreticalGHK peptide has robust complexing ability with Cu ions18

  • theoreticalGHK peptide has high affinity for Cu ions18

How the body handles it

Based on 2 human study findings, 2 in vitro findings and 2 theoretical findings.

  • human studyGHK-Cu is a naturally occurring tri-peptide present in human plasma that can be released from tissues in case of injury1

  • human studyGHK is a naturally occurring peptide found in human serum with levels averaging 200 ng/ml at age 20 but declining to an average of 80 ng/ml by age 6012

  • in vitroGHK-Cu@CMHA exhibits sustained release properties for 7 days5

  • in vitroStable GHK-Cu-loaded liposome systems of small sizes (approx. 100 nm) were obtained11

  • theoreticalGHK-Cu is a fairly hydrophilic compound with limited permeation through the lipophilic stratum corneum6

  • theoreticalLiposomes capable of encapsulating GHK-Cu may improve its permeation potential6

Safety and side effects

Based on 1 human study finding, 1 animal finding, 5 expert opinion findings and 1 theoretical finding.

  • human studyGHK-Cu was found to be non-irritating and more effective than vitamin C and retinoic acid in the 12-week photoaging study15

  • animalGHK-Cu attenuates lung inflammation and fibrosis in silicosis mice without significant systemic toxicity9

  • expert opinionRemaining challenges exist in clinical translation, production standardization, and large-scale quality assurance2

  • expert opinionSystemic (injectable) use for anti-aging, neuroprotection, or anti-inflammatory effects is speculative — animal data and gene expression studies only14

  • expert opinionGHK-Cu is an unapproved peptide operating largely outside of regulatory oversight in a parallel gray market16

  • expert opinionRigorous human safety data for unapproved peptides like GHK-Cu are scarce16

  • expert opinionThere is potential for serious harm to patients from unapproved peptides like GHK-Cu16

  • theoreticalGHK-Cu and Pal-GHK formulations encounter challenges due to their hydrophilic nature and instability8

What people use it for

Based on 11 animal findings, 1 in vitro finding, 2 expert opinion findings and 5 theoretical findings.

  • animalGHK-Cu tightens loose skin and reverses thinning of aged skin1

  • animalGHK-Cu repairs protective skin barrier proteins1

  • animalGHK-Cu improves skin firmness, elasticity, and clarity1

  • animalGHK-Cu reduces fine lines, depth of wrinkles, and improves structure of aged skin1

  • animalGHK-Cu stimulates wound healing1

  • animalGHK-Cu protects skin cells from UV radiation1

  • animalGHK-Cu increases hair growth and thickness, enlarges hair follicle size1

  • animalGHK-Cu treatment reduced cigarette smoking-induced muscle mass loss in C57BL/6 mice at 0.2 and 2 mg/kg doses10

Show 11 more findings

  • animalGHK-Cu improved grip strength in CS-exposed mice10

  • animalPreliminary observations suggest GHK can partially reverse cognitive impairment in aging mice by targeting anti-inflammatory and epigenetic pathways12

  • animalIntra-articular supplementation with GHK-Cu improved graft healing following ACLR in rat, but beneficial effects could not last as treatment discontinued13

  • in vitroGHK-Cu@CMHA gel has good flowability and injectability5

  • expert opinionGHK-Cu has evolved from a dermatological bioactive ingredient into a representative model system linking coordination chemistry, peptide bioactivity, and biomanufacturing engineering2

  • expert opinionGHK-Cu (glycyl-L-histidyl-L-lysine copper) is marketed direct to patients16

  • theoreticalGHK-Cu displays beneficial properties via reducing fine lines and wrinkles6

  • theoreticalGHK-Cu displays beneficial properties via tightening skin6

  • theoreticalGHK-Cu displays beneficial properties via improving skin elasticity6

  • theoreticalGHK has properties for wound healing and prevention/reduction of wrinkles8

  • theoreticalGHK-Cu is an anti-aging and wound-healing copper-binding peptide11

Other findings

Based on 1 in vitro finding, 3 expert opinion findings and 1 theoretical finding.

  • in vitroGHK-modified asymmetric nanochannels achieved a detection limit of 10 μM for Cu ions18

  • expert opinionTransport of liposomes containing GHK-Cu received little attention in literature6

  • expert opinionGHK-Cu was first isolated from human plasma in 1973 by Dr. Loren Pickart15

  • expert opinionBy age 60, the levels of GHK in the plasma drop by as much as 60% from the levels in our twenties15

  • theoreticalGHK-Cu and Pal-GHK are metal complex and palmitoylated derivatives of GHK, respectively8

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

No human data exist for injectable/systemic GHK-Cu.

Multiple sources agree that all published human efficacy data are from topical application, that no human trial has tested subcutaneous or intramuscular injection, that no subcutaneous pharmacokinetics exist in any species, and that systemic use for anti-aging, neuroprotection or anti-inflammatory effects is speculative and based on animal and gene-expression data only. Detailed injectable dosing protocols in circulation are extrapolated from animal data.

Contested

The '4,000+ genes' claim rests on a single unreplicated reanalysis, per one source.

Peerless Peptides states the claim that GHK reprograms more than four thousand genes derives from a single 2014 reanalysis of three cancer-cell-line microarray profiles and has not been independently replicated. Other sources repeat the figure as established (>4,000 genes, 4,048 at 1 µM, ~6% of the genome) attributed to the Broad Institute Connectivity Map or 2012 Pickart analysis, and report percentages varying between 31.2%, ~31%, and ~32%.

Limited evidence

The key positive wound-healing RCT is old and unreplicated, with no placebo-controlled wrinkle RCTs.

Apotheon notes the positive diabetic ulcer RCT (77% vs 45%, N=40) remains unreplicated after 30 years, and that no placebo-controlled wrinkle RCTs exist despite decades of cosmetic use. A 2006 controlled trial and a post-CO2 laser RCT (N=13) found no objective benefit.

Contested

Reported molecular weight of the GHK-Cu complex varies between sources.

Values given for the GHK-Cu complex include ~402.9 (with free peptide 340.4), ~403 Da (and a 467 Da figure), 403.9 Da, and ~401.9 Da across different vendor and PK profiles.

Limited evidence

Pharmacokinetic parameters for injected GHK-Cu are estimates, not measurements.

HealthRx presents half-life (0.5–1 h), peak time (15–30 min), and bioavailability (80–95%) as estimates, and states no formal FDA pharmacokinetic study has been filed and no published subcutaneous PK exist in any species.

Limited evidence

Most sources are low-tier vendor/educational web pages.

A large share of the claims — including dosing protocols, plasma-level figures, and mechanism summaries — originate from tier-3 and tier-4 vendor or aggregator web pages rather than primary studies; higher-tier PubMed sources are largely reviews or animal/in-vitro studies, and one review flags GHK-Cu as an unapproved gray-market peptide with scarce rigorous human safety data.

Sold inside these blends

Commercial products that contain this compound alongside others.

Using it with other compounds

Check a stack
  • MOTS-cSame downstream effect

    No documented conflict

    GHK-Cu and MOTS-c both blunt inflammation and support mitochondrial antioxidant defenses through separate routes. GHK-Cu activates SIRT1, delivers copper to superoxide dismutase to lower ROS, and suppresses NF-kB and inflammatory cytokines including IL-6, TNF-alpha and IL-1beta. MOTS-c activates AMPK and engages the Keap1-Nrf2/ARE axis to drive a cytoprotective antioxidant stress response. They reach a common antioxidant, anti-inflammatory output from distinct origins, and nothing in their described biology suggests a conflict.

    Tier 4Theoretical — not established

    Shares anti inflammatory · mitochondrial function

  • KPVSame downstream effect

    No documented conflict

    Both GHK-Cu and KPV reduce inflammation and lower pro-inflammatory cytokines (IL-6, TNF-α, IL-1β), each acting on NF-κB signaling. GHK-Cu suppresses NF-κB alongside copper-dependent antioxidant enzyme support, while KPV, an α-MSH fragment, stabilizes IκBα and inhibits the IKK complex. They reach an anti-inflammatory endpoint by distinct routes. Nothing described suggests a conflict between them.

    Tier 4Theoretical — not established

    Shares anti inflammatory · NF kB modulation

  • SS-31Same downstream effect

    No documented conflict

    GHK-Cu reduces reactive oxygen species by activating SOD/SOD2 and delivers copper to cuproenzymes including cytochrome c oxidase, while lowering IL-6, TNF-α and IL-1β. SS-31 binds cardiolipin to stabilize ETC supercomplexes and cytochrome c, cutting mitochondrial ROS and modulating inflammation. Both converge on reduced oxidative stress and supported mitochondrial function through different molecular routes. Nothing in their described biology suggests a conflict between them.

    Tier 4Theoretical — not established

    Shares mitochondrial function · anti inflammatory

  • LL-37Complementary

    May be complementary

    GHK-Cu stimulates collagen/elastin synthesis, angiogenesis and antioxidant defenses while suppressing NF-κB, and LL-37 contributes antimicrobial defense plus angiogenic and epithelializing wound-healing effects. Their distinct mechanisms both support skin remodeling and tissue repair, making them a reasonable complementary combination for wound/skin contexts.

    Tier 4Theoretical — not established
  • TB-500Complementary

    May be complementary

    GHK-Cu stimulates collagen/GAG synthesis and ECM remodeling while TB-500 (Thymosin β4 fragment) sequesters G-actin to promote cell migration, angiogenesis and inflammation resolution. Different mechanisms both converge on angiogenesis, integrin/ECM remodeling and NF-κB suppression — a classic complementary regeneration pairing.

    Tier 3Largely anecdotal — commonly discussed
  • GLOWSame mechanism

    Worth caution

    GHK-Cu is already one of the three peptides inside GLOW. Adding a separate GHK-Cu product on top of GLOW means you are dosing the same ingredient twice, which raises the risk of overshooting rather than adding new benefit. If you want more GHK-Cu, adjust the blend dose rather than stacking a duplicate.

    Tier 3Largely anecdotal — commonly discussed

    Shares tissue repair · angiogenesis · anti inflammatory · collagen synthesis · NF kB modulation · VEGF upregulation · dermal matrix

  • PTD-DBMComplementary

    May be complementary

    Both peptides converge on hair-follicle activation and collagen/dermal-matrix building, but by different routes: PTD-DBM releases the CXXC5 brake to boost Wnt/beta-catenin signaling in follicle cells, while GHK-Cu delivers copper to collagen/elastin-building enzymes and has its own Wnt/beta-catenin hair-growth activity. Used together (typically topically) they can reinforce hair regrowth and skin/collagen quality through non-redundant mechanisms.

    Tier 4Theoretical — not established

    Timing Both are commonly applied topically to scalp/skin; can be layered in the same routine.

    Shares collagen synthesis · dermal matrix · tissue repair

  • BPC-157Complementary

    May be complementary

    Both peptides promote wound healing, collagen synthesis and angiogenesis through overlapping PI3K/Akt, mTOR, TGF-β and AMPK signaling, but via distinct entry points: BPC-157 through VEGFR2/eNOS and growth-factor induction, GHK-Cu through copper delivery, lysyl-oxidase-driven collagen/elastin crosslinking and Nrf2 antioxidant activation. They are frequently combined for skin/connective-tissue remodeling.

    Tier 4Theoretical — not established
  • EpithalonSame downstream effect

    No documented conflict

    Both peptides reduce oxidative stress by distinct routes. Epithalon shows antioxidant activity with mitochondrial ROS modulation and acts on telomerase and the p16/p21 senescence pathway. GHK-Cu activates antioxidant defenses (SOD/SOD2, reduced ROS) via SIRT1 and copper delivery to cuproenzymes including superoxide dismutase. They converge on antioxidant/mitochondrial function through different mechanisms. Nothing in their described biology suggests a conflict between them.

    Tier 4Theoretical — not established

    Shares mitochondrial function

Safety and side effects

Safety and Side Effects

No human data exist for injectable or systemic GHK-Cu. Peerless Peptides, Apotheon, and others state that the human safety and efficacy of injectable GHK-Cu have not been established, with the injectable dossier being animal-model and in-vitro only and no human randomized trials14. A review (PMID 41966639) describes GHK-Cu as an unapproved peptide marketed direct to patients, operating largely outside regulatory oversight in a parallel gray market, with scarce rigorous human safety data and potential for serious harm16. Peptidings states the FDA has flagged injectable GHK-Cu as a high-risk compounding category(vendor claim).

Topical safety signals

Peptide Garden cites a 2023 review of 12 topical studies (n=512 subjects) that found only transient redness (4.2%) and itching (2.8%)(vendor claim) — a figure reported by a single vendor profile. Peptide Guides states no serious adverse events have been documented in published topical trials at the doses studied(vendor claim).

Copper-related concerns with systemic use

Peptidings notes that copper accumulation is a potential concern with chronic systemic use, that excessive copper can cause hepatotoxicity, hemolysis, and neurological complications, that hypersensitivity to the copper component is possible, and that no published human safety data exist for injectable GHK-Cu(vendor claim). Peptidings also notes that therapeutic copper dosing for deficiency is only 4–8 mg daily, and that no clinical trials have established safe systemic dosing ranges for GHK-Cu(vendor claim). Silicosis animal work (PMID 38879894) reported attenuation of lung fibrosis without significant systemic toxicity in mice9, but this is an animal finding, not a human safety demonstration.

Translation caveats

A journal review (PMID 41-series) notes remaining challenges for GHK-Cu in clinical translation, production standardization, and large-scale quality assurance2. Most dosing protocols, plasma-level figures, and mechanism summaries in circulation originate from tier-3/tier-4 vendor or aggregator web pages rather than primary studies.

Reconstitution and handling

Dosing

No dose has been established for this compound. DrOracle states GHK-Cu has no FDA-approved indications and no established human dosing regimens, with all efficacy evidence coming from animal models and in-vitro studies(vendor claim). Peptidings notes published GHK-Cu dosing falls into two categories — topical formulation studies and preclinical systemic administration in animal models — with no established human medical dosing, and that no clinical trials have established safe systemic dosing ranges(vendor claim). The figures below are what sources report, not guidance.

Topical (the route with human data)

  • Apotheon cites a topical dose of 0.5–3% over 8–12 weeks; Gethealthspan cites 0.1–1% topical concentrations14.
  • PeptideWiki lists topical use at 1–2 mg/mL, 1–2× daily for 4–12 weeks(vendor claim).
  • Controlled trials reported significant improvements at concentrations of 0.1–1%.

Injectable / systemic (vendor and preclinical only — no human trials)

  • PeptideWiki (a tier-3 aggregator page) lists injectable dosing of 1–3 mg(vendor claim); no human trial supports this figure.
  • Peptides Power (a vendor) describes a conservative subcutaneous protocol of 1.0 mg in weeks 1–4, 1.5 mg in weeks 5–8, and 2.0 mg in weeks 9–12+, dosed once daily 5 days per week, and an alternative of 2.0 mg three times weekly (~6 mg/week), with typical cycles of 8–12 weeks extendable up to 16 weeks(vendor claim). These are vendor protocol templates; no human trial has tested subcutaneous GHK-Cu, and Peerless Peptides states no published subcutaneous pharmacokinetics exist in any species.
  • Preclinical animal doses reported by DrOracle: intranasal 15 mg/kg daily for 2 months in mice; intra-articular 0.3–3 mg/mL weekly for 4 weeks in ACL reconstruction rats; systemic 15 mg/kg/day in acute lung injury mice; and transdermal microneedle delivery of 134 nanomoles over 9 hours. A cigarette-smoking mouse study used 0.2 and 2 mg/kg10.

Reconstitution (vendor description)

Peptides Power describes reconstituting a 50 mg vial with 3.0 mL of sterile or bacteriostatic water to give a 16.67 mg/mL concentration(vendor claim) — equivalent to 167 mcg per 0.01 mL (1 unit) on a U-100 insulin syringe. On that vendor's protocol, 1.0 mg corresponds to ~6 units, 1.5 mg to ~9 units, and 2.0 mg to ~12 units.

Storage

Peptides Power advises storing lyophilized GHK-Cu powder at -20°C or below, away from moisture and light, and refrigerating reconstituted peptide at 2–8°C for use within 30 days(vendor claim).

Formulation and permeation notes

HealthRx notes GHK-Cu's molecular weight is below the 500 Da threshold for stratum corneum penetration and can potentially cross it, with ex-vivo human skin models showing measurable dermal concentrations, and a 2015 Badenhorst study confirming copper peptide complexes permeate porcine skin in appropriate vehicles(vendor claim). Other sources report GHK-Cu is hydrophilic with limited permeation through the lipophilic stratum corneum, and that liposomal encapsulation, metal complexation, hydrophobic modification, cell-penetrating peptides, or microneedle pretreatment may improve permeation6,8. A liposome study (PMID 37896245) reported stable ~100 nm GHK-Cu-loaded liposomes, with cationic liposomes achieving 31.7 ± 0.9% encapsulation efficiency versus 20.0 ± 2.8% for anionic11. An injectable hydrogel study (PMID 40716276) reported GHK-Cu@CMHA exhibited sustained release for 7 days with good flowability and injectability5.

Sources

Ordered by evidence quality — the strongest first.

  1. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2018
  2. GHK-Cu as a multifunctional copper peptide: synthesis routes, process engineering and emerging applications(opens in a new tab)
    Tier 2Web · journal.hep.com.cn · 2026
  3. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  4. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  5. An injectable hydroxyapatite microsphere filler loaded with GHK-Cu tripeptide for anti-Inflammatory and antioxidant.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  6. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  7. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  8. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  9. The glycyl-l-histidyl-l-lysine-Cutripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  10. Glycyl-l-histidyl-l-lysine-Curescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  11. Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  12. The potential of GHK as an anti-aging peptide.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  13. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2015
  14. GHK-Cu · Compound Monograph | Apotheon(opens in a new tab)
    Tier 3Web · apotheon.io
  15. GHK-Cu Peptide: Evidence-Based Benefits, Mechanisms, Dosage, and Safety(opens in a new tab)
    Tier 3Web · amdalliance.org
  16. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  17. Phenothiazine-Based Cu(II)-Selective Fluorescent Sensor: GHK-Cu Sensing Applications.(opens in a new tab)
    Tier 4PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  18. Ultrasensitive and Label-Free Detection of Copper Ions by GHK-Modified Asymmetric Nanochannels.(opens in a new tab)
    Tier 4PubMed · pubmed.ncbi.nlm.nih.gov · 2023

See something wrong or out of date on this page? Report it.